Bernard E Weissman

List of Publications by Year
in descending order

28 papers	2,102 citations	361413 20 h-index	526287 27 g-index
31 all docs	31 docs citations	31 times ranked	2641 citing authors

#	Article	IF	Citations
1	Differences in the microbial profiles of early stage endometrial cancers between Black and White women. Gynecologic Oncology, 2022, , .	1.4	11
2	TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice. Oncogene, 2022, 41, 3423-3432.	5.9	7
3	Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines. Gynecologic Oncology, 2021, 160, 568-578.	1.4	21
4	A cytoskeletal function for PBRM1 reading methylated microtubules. Science Advances, 2021, 7, .	10.3	17
5	The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer. PLoS ONE, 2020, 15, e0235705.	2.5	44
6	Loss of SWI/SNF Chromatin Remodeling Alters NRF2 Signaling in Nonâ€“Small Cell Lung Carcinoma. Molecular Cancer Research, 2020, 18, 1777-1788.	3.4	24
7	Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthaseâ€“Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. Clinical Cancer Research, 2020, 26, 4402-4413.	7.0	21
8	A conditional mouse expressing an activating mutation in <scp>NRF2</scp> displays hyperplasia of the upper gastrointestinal tract and decreased white adipose tissue. Journal of Pathology, 2020, 252, 125-137.	4.5	16
9	Small-Cell Carcinoma of the Ovary, Hypercalcemic Typeâ€“Genetics, New Treatment Targets, and Current Management Guidelines. Clinical Cancer Research, 2020, 26, 3908-3917.	7.0	82
10	Re-expression of SMARCA4/BRG1 in small cell carcinoma of ovary, hypercalcemic type (SCCOHT) promotes an epithelial-like gene signature through an AP-1-dependent mechanism. ELife, 2020, 9, .	6.0	19
11	Remodeling the cancer epigenome: mutations in the SWI/SNF complex offer new therapeutic opportunities. Expert Review of Anticancer Therapy, 2019, 19, 375-391.	2.4	30
12	NRF2 Activation in Cancer: From DNA to Protein. Cancer Research, 2019, 79, 889-898.	0.9	140
13	Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition. Clinical Cancer Research, 2018, 24, 1932-1943.	7.0	51
14	High Frequency of Ovarian Cyst Development in Vhl;Snf5 Mice. American Journal of Pathology, 2018, 188, 1510-1516.	3.8	0
15	Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type. Molecular Cancer Therapeutics, 2018, 17, 2767-2779.	4.1	50
16	The Cancer/Testes (CT) Antigen HORMAD1 promotes Homologous Recombinational DNA Repair and Radioresistance in Lung adenocarcinoma cells. Scientific Reports, 2018, 8, 15304.	3.3	43
17	The histone methyltransferase <scp>EZH2</scp> is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type. Journal of Pathology, 2017, 242, 371-383.	4.5	78
18	Dual loss of the <scp>SWI</scp>/<scp>SNF</scp> complex <scp>ATPases SMARCA4</scp>/<scp>BRG1</scp> and <scp>SMARCA2</scp>/<scp>BRM</scp> is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. Journal of Pathology, 2016, 238, 389-400.	4.5	169

#	Article	IF	Citations
19	SNF5/INI1 Deficiency Redefines Chromatin Remodeling Complex Composition during Tumor Development. Molecular Cancer Research, 2014, 12, 1574-1585.	3.4	31
20	BRG1/SMARCA4 Inactivation Promotes Nonâ€“Small Cell Lung Cancer Aggressiveness by Altering Chromatin Organization. Cancer Research, 2014, 74, 6486-6498.	0.9	104
21	Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Research, 2003, 63, 560-6.	0.9	282
22	Compensation of BRG-1 Function by Brm. Journal of Biological Chemistry, 2002, 277, 4782-4789.	3.4	97
23	Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression. Oncogene, 2002, 21, 1196-1207.	5.9	141
24	Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies. Journal of Cellular Physiology, 2001, 186, 136-145.	4.1	172
25	Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2 and c-Myc expression. Oncogene, 2001, 20, 3258-3265.	5.9	157
26	The BRG-1 Subunit of the SWI/SNF Complex Regulates CD44 Expression. Journal of Biological Chemistry, 2001, 276, 9273-9278.	3.4	80
27	Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies. Journal of Cellular Physiology, 2001, 186, 136-145.	4.1	126
28	Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors. Oncogene, 1999, 18, 7559-7565.	5.9	84